Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LanScape: Basal Plus One vs Biphasic Insulin in T2DM
NCT00965549Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jul 2009
- Primary completion
- Dec 2012
- Modality
- Peptides
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of insulin glulisine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Glycosylated Haemoglobin at 32 weeks. Started Jul 2009; status: completed.
02
Drugs
insulin glulisine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00965549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00965549.